A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1

Trial Profile

A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Danoprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Ascletis
  • Most Recent Events

    • 30 Jul 2018 According to an Ascletis media release, this phase III study of Ganovo (Danoprevir) won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association and was accepted by Professor Wei Lai, the Director of the Institute of Hepatology of Peking University, also the principal investigator of Ganovos clinical trial.
    • 12 Jun 2018 According to the Ascletis media release, China Food and Drug Administration (CFDA) has approved new drug application for Ganovo for the treatment of viral hepatitis C.
    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top